- Lonza (LONN) Q1 sales €/CHF 3.4B, +16% FX-adjusted. CORE EBITDA margin 34.8% (+4.4pp). Company raised full-year core EBITDA margin guidance to 33–34% of sales.
- Lonza (LONN) to sell Capsules & Health Ingredients, deal closing before end-2026; launches expedited CHF500M buyback to return surplus capital amid shift to pure-play CDMO.
TradingView
Key facts: Lonza Q1 +16%, margins up; Capsules & HI, CHF500M buyback
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- SIX:LONN
- Language
- English
Lonza (LONN) Q1 sales €/CHF 3.4B, +16% FX-adjusted. CORE EBITDA margin 34.8% (+4.4pp). Company raised full-year core EBITDA margin guidance to 33–34% of sales.Lonza (LONN) to sell